Rapid conformational epitope mapping of anti-gp120 antibodies with a designed mutant panel displayed on yeast.

[1]  P. Çalık,et al.  Production of recombinant proteins by yeast cells. , 2012, Biotechnology advances.

[2]  Lynn Morris,et al.  Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein , 2012, The Journal of experimental medicine.

[3]  Hanqin Peng,et al.  HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120 , 2012, Proceedings of the National Academy of Sciences.

[4]  D. Burton,et al.  An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site. , 2012, Vaccine.

[5]  M. Nussenzweig,et al.  Enhanced HIV-1 neutralization by antibody heteroligation , 2012, Proceedings of the National Academy of Sciences.

[6]  Yan Liu,et al.  A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield , 2011, Science.

[7]  Pham Phung,et al.  Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.

[8]  Mario Roederer,et al.  Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing , 2011, Science.

[9]  Ron Diskin,et al.  Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.

[10]  Feng Gao,et al.  Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals , 2011, Journal of Virology.

[11]  Barney S. Graham,et al.  Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 , 2011, Journal of Virology.

[12]  Andrew S. Bennett,et al.  Fine epitope mapping of monoclonal antibodies against hemagglutinin of a highly pathogenic H5N1 influenza virus using yeast surface display , 2011, Biochemical and Biophysical Research Communications.

[13]  L. Stamatatos,et al.  Computational protein design using flexible backbone remodeling and resurfacing: case studies in structure-based antigen design. , 2011, Journal of molecular biology.

[14]  Ming Li,et al.  Genetic Signatures in the Envelope Glycoproteins of HIV-1 that Associate with Broadly Neutralizing Antibodies , 2010, PLoS Comput. Biol..

[15]  M. Nussenzweig,et al.  Human anti–HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness , 2010, The Journal of experimental medicine.

[16]  Tongqing Zhou,et al.  Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 , 2010, Science.

[17]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[18]  Dennis R. Burton,et al.  A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals , 2010, PLoS pathogens.

[19]  Dennis R Burton,et al.  Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens , 2010, Proceedings of the National Academy of Sciences.

[20]  Jamie B. Spangler,et al.  Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling , 2010, Proceedings of the National Academy of Sciences.

[21]  D. Burton,et al.  Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1 , 2010, Proceedings of the National Academy of Sciences.

[22]  D. Burton,et al.  Rational antibody-based HIV-1 vaccine design: current approaches and future directions. , 2010, Current opinion in immunology.

[23]  L. Stamatatos,et al.  Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects. , 2010, Vaccine.

[24]  David C Montefiori,et al.  The role of antibodies in HIV vaccines. , 2010, Annual review of immunology.

[25]  David C Montefiori,et al.  Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. , 2010, Virology.

[26]  D. Montefiori,et al.  Breadth of Neutralizing Antibodies Elicited by Stable, Homogeneous Clade A and Clade C HIV-1 gp140 Envelope Trimers in Guinea Pigs , 2010, Journal of Virology.

[27]  Young Do Kwon,et al.  Structure of HIV-1 gp120 with gp41-Interactive Region: Layered Architecture and Basis of Conformational Mobility , 2009 .

[28]  Tongqing Zhou,et al.  Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120 , 2009, Science.

[29]  Pham Phung,et al.  Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.

[30]  Yih-En Andrew Ban,et al.  Challenges for structure-based HIV vaccine design , 2009, Current opinion in HIV and AIDS.

[31]  F. Pereyra,et al.  A method for identification of HIV gp140 binding memory B cells in human blood. , 2009, Journal of immunological methods.

[32]  Richard T. Wyatt,et al.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals , 2009, Nature.

[33]  Tongqing Zhou,et al.  Enhanced Exposure of the CD4-Binding Site to Neutralizing Antibodies by Structural Design of a Membrane-Anchored Human Immunodeficiency Virus Type 1 gp120 Domain , 2009, Journal of Virology.

[34]  David F. Smith,et al.  An Engineered Saccharomyces cerevisiae Strain Binds the Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody 2G12 and Elicits Mannose-Specific gp120-Binding Antibodies , 2008, Journal of Virology.

[35]  K Dane Wittrup,et al.  Yeast surface display for protein engineering and characterization , 2007, Current Opinion in Structural Biology.

[36]  Peter D. Kwong,et al.  Characterization of Human Immunodeficiency Virus Type 1 Monomeric and Trimeric gp120 Glycoproteins Stabilized in the CD4-Bound State: Antigenicity, Biophysics, and Immunogenicity , 2007, Journal of Virology.

[37]  Tongqing Zhou,et al.  Structural definition of a conserved neutralization epitope on HIV-1 gp120 , 2007, Nature.

[38]  Leonard A. Smith,et al.  Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. , 2007, Journal of molecular biology.

[39]  T. Oliphant,et al.  Antibody Recognition and Neutralization Determinants on Domains I and II of West Nile Virus Envelope Protein , 2006, Journal of Virology.

[40]  K Dane Wittrup,et al.  Isolating and engineering human antibodies using yeast surface display , 2006, Nature Protocols.

[41]  D. Burton,et al.  GP120: target for neutralizing HIV-1 antibodies. , 2006, Annual review of immunology.

[42]  J. Kuriyan,et al.  Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast , 2005, Proteins.

[43]  Yang Liu,et al.  Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Robyn L Stanfield,et al.  Antibody vs. HIV in a clash of evolutionary titans. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Doms,et al.  Comparing Antigenicity and Immunogenicity of Engineered gp120 , 2005, Journal of Virology.

[46]  Chris Doane,et al.  Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus , 2005, Nature Medicine.

[47]  J. Sodroski,et al.  Characterization of the Outer Domain of the gp120 Glycoprotein from Human Immunodeficiency Virus Type 1 , 2004, Journal of Virology.

[48]  D. Burton,et al.  Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12. , 2004, Protein engineering, design & selection : PEDS.

[49]  K Dane Wittrup,et al.  Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display. , 2004, Journal of molecular biology.

[50]  Wayne C Koff,et al.  HIV vaccine design and the neutralizing antibody problem , 2004, Nature Immunology.

[51]  D. Burton,et al.  Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies. , 2003, Trends in molecular medicine.

[52]  Christoph Grundner,et al.  Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1 , 2003, Journal of Virology.

[53]  A. Sali,et al.  Comparative protein structure modeling by iterative alignment, model building and model assessment. , 2003, Nucleic acids research.

[54]  Dennis R. Burton,et al.  Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design , 2003, Journal of Virology.

[55]  Paul W. H. I. Parren,et al.  Fine Mapping of the Interaction of Neutralizing and Nonneutralizing Monoclonal Antibodies with the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120 , 2003, Journal of Virology.

[56]  Peter D. Kwong,et al.  HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites , 2002, Nature.

[57]  H. Katinger,et al.  The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of α1→2 Mannose Residues on the Outer Face of gp120 , 2002, Journal of Virology.

[58]  Peter D. Kwong,et al.  The Mannose-Dependent Epitope for Neutralizing Antibody 2G12 on Human Immunodeficiency Virus Type 1 Glycoprotein gp120 , 2002, Journal of Virology.

[59]  C. Broder,et al.  UvA-DARE ( Digital Academic Repository ) Neutralizing antibodies to the HIV-1 envelope glycoproteins , 2009 .

[60]  A. Sali,et al.  Statistical potentials for fold assessment , 2009 .

[61]  B. Korber,et al.  Evolutionary and immunological implications of contemporary HIV-1 variation. , 2001, British medical bulletin.

[62]  K D Wittrup,et al.  Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[63]  W A Hendrickson,et al.  Energetics of the HIV gp120-CD4 binding reaction. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[64]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[65]  Eric T. Boder,et al.  Yeast surface display for screening combinatorial polypeptide libraries , 1997, Nature Biotechnology.

[66]  A. Trkola,et al.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.

[67]  D R Burton,et al.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. , 1994, Science.

[68]  D R Burton,et al.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 , 1994, Journal of virology.

[69]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[70]  J. Sodroski,et al.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding , 1993, Journal of virology.

[71]  P. Sharp,et al.  Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation , 1992, Journal of virology.

[72]  J. Sodroski,et al.  Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein , 1992, Journal of virology.

[73]  D R Burton,et al.  A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[74]  T. Hideshima,et al.  An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. , 1991, Journal of immunology.

[75]  P. Argos,et al.  Suggestions for "safe" residue substitutions in site-directed mutagenesis. , 1991, Journal of molecular biology.

[76]  J. Sodroski,et al.  Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding , 1990, Journal of virology.

[77]  C. Chothia,et al.  Principles of protein–protein recognition , 1975, Nature.

[78]  R. Grantham.  Amino Acid Difference Formula to Help Explain Protein Evolution , 1974, Science.